Benzinga··Vandana SinghMerck's $6.7B Terns Deal Could Attract Rival Bidders as Patent Cliff Looms
Merck agrees to acquire Terns Pharmaceuticals for $6.7B to strengthen pipeline before Keytruda's 2028 patent expiry, but analysts suggest competing bids may emerge.
MRKNVSRVMDRVMDWTERNacquisitionM&A